Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ATF1 | P18846 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118471 | 0.83 | PLAU (0.42) | NOTUMATF1NFKB1GLP1RKDM5B | |
| SCHEMBL20457090 | 0.81 | CCR1 (0.35) | CCR1CCR5CCR8AXLPRKCI | |
| SCHEMBL24843396 | 0.80 | KDM4E (0.33) | ATF1NFKB1GLP1R | |
| SCHEMBL23099873 | 0.77 | CCR1 (0.35) | CCR1CCR5CCR8KDM5B | |
| SCHEMBL25584916 | 0.72 | HTT (0.42) | ATF1NFKB1GLP1R | |
| SCHEMBL21279619 | 0.72 | KDM5B (0.36) | CCR1CCR5CCR8KDM5B | |
| SCHEMBL2146161 | 0.71 | ATF1 (0.37) | NOTUMATF1NFKB1GLP1R | |
| SCHEMBL23508729 | 0.71 | SMN1; SMN2 (0.38) | CCR1CCR5CCR8NOTUM | |
| SCHEMBL12203584 | 0.71 | NFKB1 (0.44) | ATF1NFKB1GLP1R | |
| SCHEMBL8356225 | 0.71 | ALDH1A1 (0.39) | ATF1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230026907-A1 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | ORION CORP (FI) | 2023-01-26 | — | — | US | disclosed |
| WO-2021047622-A1 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026907-A1 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN11A, HCN4, CACNA1F | CCR1 3678/4885CCR5 3283/4885CCR8 3353/4885 |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN11A, HCN4, CACNA1F | CCR1 3678/4885CCR5 3283/4885CCR8 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.